Compare Citius Pharmaceuticals Inc (CTXR) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Wheaton Precious Metals Corp trades at $135.8 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 3045.5× Citius Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WPM | |
|---|---|---|
Market Cap | $20.01M | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $165.72 |
52-Week Low | $0.48 | $91.02 |
Enterprise Value | $16.23M | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Wheaton Precious Metals (WPM) trades at $133.39, down 0.6% for the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.19, supported by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income reaching $1.47 billion, reflecting robust profitability margins.
The outlook remains positive with an 80% analyst buy rating and a $161.75 consensus price target, indicating ~21% upside. Key risks include reliance on commodity prices and projected negative cash flow in 2026. The stock's premium valuation (P/E 29.82) requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
